202 related articles for article (PubMed ID: 36928816)
1. A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer.
Assaf ZJF; Zou W; Fine AD; Socinski MA; Young A; Lipson D; Freidin JF; Kennedy M; Polisecki E; Nishio M; Fabrizio D; Oxnard GR; Cummings C; Rode A; Reck M; Patil NS; Lee M; Shames DS; Schulze K
Nat Med; 2023 Apr; 29(4):859-868. PubMed ID: 36928816
[TBL] [Abstract][Full Text] [Related]
2. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC).
Ricciuti B; Jones G; Severgnini M; Alessi JV; Recondo G; Lawrence M; Forshew T; Lydon C; Nishino M; Cheng M; Awad M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771889
[TBL] [Abstract][Full Text] [Related]
3. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
4. Personalized circulating tumor DNA detection to monitor immunotherapy efficacy and predict outcome in locally advanced or metastatic non-small cell lung cancer.
Cheng L; Gao G; Zhao C; Wang H; Yao C; Yu H; Yao J; Li F; Guo L; Jian Q; Chen X; Li X; Zhou C
Cancer Med; 2023 Jul; 12(13):14317-14326. PubMed ID: 37184093
[TBL] [Abstract][Full Text] [Related]
5. Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
Vega DM; Nishimura KK; Zariffa N; Thompson JC; Hoering A; Cilento V; Rosenthal A; Anagnostou V; Baden J; Beaver JA; Chaudhuri AA; Chudova D; Fine AD; Fiore J; Hodge R; Hodgson D; Hunkapiller N; Klass DM; Kobie J; Peña C; Pennello G; Peterman N; Philip R; Quinn KJ; Raben D; Rosner GL; Sausen M; Tezcan A; Xia Q; Yi J; Young AG; Stewart MD; Carpenter EL; Aggarwal C; Allen J
JCO Precis Oncol; 2022 Aug; 6():e2100372. PubMed ID: 35952319
[TBL] [Abstract][Full Text] [Related]
6. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
[TBL] [Abstract][Full Text] [Related]
7. Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors.
Hu Y; Narayan A; Xu Y; Wolfe J; Vu D; Trinh T; Kantak C; Ivy SP; Eder JP; Deng Y; LoRusso P; Kim JW; Patel AA
JCO Precis Oncol; 2024 Feb; 8():e2300289. PubMed ID: 38412387
[TBL] [Abstract][Full Text] [Related]
8. Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer.
Pellini B; Madison RW; Childress MA; Miller ST; Gjoerup O; Cheng J; Huang RSP; Krainock M; Gupta P; Zou W; Shames DS; Moshkevich S; Ballinger M; Liu MC; Young A; Srivastava MK; Oxnard GR; Socinski MA
Clin Cancer Res; 2023 Nov; 29(22):4596-4605. PubMed ID: 37702716
[TBL] [Abstract][Full Text] [Related]
9. ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors.
Nie W; Wang ZJ; Zhang K; Li B; Cai YR; Wen FC; Zhang D; Bai YZ; Zhang XY; Wang SY; Cheng L; Zhong H; Liu L; Wang J; Han BH
BMC Med; 2022 May; 20(1):170. PubMed ID: 35509036
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.
Roosan MR; Mambetsariev I; Pharaon R; Fricke J; Husain H; Reckamp KL; Koczywas M; Massarelli E; Bild AH; Salgia R
Chest; 2021 Sep; 160(3):1095-1107. PubMed ID: 33878340
[TBL] [Abstract][Full Text] [Related]
11. ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy.
Zou W; Yaung SJ; Fuhlbrück F; Ballinger M; Peters E; Palma JF; Shames DS; Gandara D; Jiang Y; Patil NS
JCO Precis Oncol; 2021 Nov; 5():827-838. PubMed ID: 34994614
[TBL] [Abstract][Full Text] [Related]
12. Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.
Sun Y; Duan J; Fang W; Wang Z; Du X; Wang X; Li C; Cai S; Zhao J; Li S; Zhang L; Bai H; Wang J
BMC Med; 2021 Oct; 19(1):239. PubMed ID: 34615542
[TBL] [Abstract][Full Text] [Related]
13. Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment.
Provencio M; Serna-Blasco R; Franco F; Calvo V; Royuela A; Auglytė M; Sánchez-Hernández A; de Julián Campayo M; García-Girón C; Dómine M; Blasco A; Sánchez JM; Oramas J; Bosch-Barrera J; Sala MÁ; Sereno M; Ortega AL; Chara L; Hernández B; Padilla A; Coves J; Blanco R; Balsalobre J; Mielgo X; Bueno C; Jantus-Lewintre E; Molina-Vila MÁ; Romero A
Eur J Cancer; 2021 May; 149():61-72. PubMed ID: 33831609
[TBL] [Abstract][Full Text] [Related]
14. Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer.
Li N; Wang BX; Li J; Shao Y; Li MT; Li JJ; Kuang PP; Liu Z; Sun TY; Wu HQ; Ou W; Wang SY
Cancer; 2022 Feb; 128(4):708-718. PubMed ID: 35076939
[TBL] [Abstract][Full Text] [Related]
15. Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with
Ortiz-Cuaran S; Mezquita L; Swalduz A; Aldea M; Mazieres J; Leonce C; Jovelet C; Pradines A; Avrillon V; Chumbi Flores WR; Lacroix L; Loriot Y; Westeel V; Ngo-Camus M; Tissot C; Raynaud C; Gervais R; Brain E; Monnet I; Giroux Leprieur E; Caramella C; Mahier-Aït Oukhatar C; Hoog-Labouret N; de Kievit F; Howarth K; Morris C; Green E; Friboulet L; Chabaud S; Guichou JF; Perol M; Besse B; Blay JY; Saintigny P; Planchard D
Clin Cancer Res; 2020 Dec; 26(23):6242-6253. PubMed ID: 32859654
[TBL] [Abstract][Full Text] [Related]
16. Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028).
Li M; Chen J; Zhang B; Yu J; Wang N; Li D; Shao Y; Zhu D; Liang C; Ma Y; Ou Q; Hou X; Chen L
BMC Med; 2022 Nov; 20(1):398. PubMed ID: 36372873
[TBL] [Abstract][Full Text] [Related]
17. Dynamic Changes of Circulating Tumor DNA Predict Clinical Outcome in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
Weber S; van der Leest P; Donker HC; Schlange T; Timens W; Tamminga M; Hasenleithner SO; Graf R; Moser T; Spiegl B; Yaspo ML; Terstappen LWMM; Sidorenkov G; Hiltermann TJN; Speicher MR; Schuuring E; Heitzer E; Groen HJM
JCO Precis Oncol; 2021 Nov; 5():1540-1553. PubMed ID: 34994642
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of circulating tumor DNA in operable non-small cell lung cancer: a systematic review and reconstructed individual patient-data based meta-analysis.
Chen D; Guo J; Huang H; Tian L; Xie Y; Wu Q
BMC Med; 2023 Nov; 21(1):467. PubMed ID: 38012727
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA).
Wislez M; Domblides C; Greillier L; Mazières J; Monnet I; Kiakouama-Maleka L; Quantin X; Spano JP; Ricordel C; Fraisse P; Janicot H; Audigier-Valette C; Amour E; Langlais A; Rabbe N; Makinson A; Cadranel J; Laurent-Puig P; Lavolé A; Blons H
Lung Cancer; 2021 Jul; 157():124-130. PubMed ID: 34016488
[TBL] [Abstract][Full Text] [Related]
20. Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.
Goldberg SB; Narayan A; Kole AJ; Decker RH; Teysir J; Carriero NJ; Lee A; Nemati R; Nath SK; Mane SM; Deng Y; Sukumar N; Zelterman D; Boffa DJ; Politi K; Gettinger SN; Wilson LD; Herbst RS; Patel AA
Clin Cancer Res; 2018 Apr; 24(8):1872-1880. PubMed ID: 29330207
[No Abstract] [Full Text] [Related]
[Next] [New Search]
